StageMark

StageMark was a biotechnology company specializing in the development of blood-based diagnostic tests for neurodegenerative diseases, most notably Parkinson's and Alzheimer's. The company's technology platform utilized specific autoantibody profiles as biomarkers to detect disease at early, even pre-symptomatic, stages. By identifying unique "fingerprints" of autoantibodies in the blood, StageMark aimed to provide a minimally invasive, accurate, and cost-effective alternative to current diagnostic methods like PET scans or cerebrospinal fluid analysis. Their lead program, StageMark PD, focused on a diagnostic for Parkinson's disease and demonstrated high accuracy in clinical validation studies. Although the company is no longer active, its foundational research contributed significantly to the field of autoantibody-based diagnostics.